Goldman Sachs Group Inc Cellectis S.A. Transaction History

Goldman Sachs Group Inc

  • $555 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

May 14, 2024
BUY
$1.85 - $2.53 $33,684 - $46,066
18,208 New
18,208 $38,000
Q4 2022

Feb 13, 2023
BUY
$1.85 - $2.53 $33,684 - $46,066
18,208 New
18,208 $38,000
Q2 2022

Aug 15, 2022
SELL
$2.39 - $4.93 $127,202 - $262,389
-53,223 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$3.45 - $8.77 $183,619 - $466,765
53,223 New
53,223 $242,000

Others Institutions Holding CLLS

# of Institutions
31
Shares Held
9.83M
Call Options Held
0
Put Options Held
30.9K
View Full List

About Cellectis S.A.

CLLS Quotes by TradingView
  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $88.7M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email